With the high burden of metabolic disease increasing in the US, Sophia Humphreys, PharmD, Sutter Health, explains how this impacts health equity.
Amid the increasing burden of diabetes and heart failure in the US, Sophia Humphreys, PharmD, MHA, BCBBS, Sutter Health, explained how this impacts the equity of health care in an interview before her presentation at The American Journal of Managed Care® (AJMC®) Institute for Value-Based Medicine® event hosted by Sutter Health in San Francisco, California.
As the director of Formulary Management and Clinical Services, Humphreys’ “passion is to bring the highest quality medication to our patients with the lowest cost for our society.”
Transcript
Your presentation began with the increasing burden of diabetes and heart failure. What does this rapidly growing burden mean for the future of treatment and care?
That's a very good question. As you know, our population is aging; as our population ages, in the meantime, we're seeing obesity become more and more prevalent. With obesity, we see higher risk and higher incidence of diabetes. That's why we see the growing epidemiology of diabetes. As you know, diabetes is a higher risk factor for both stroke and cardiovascular issues. And we are seeing a high burden both on our patients as well as our health care system.
Sutter [Health] is a nonprofit health system. We see a diverse population here in Northern California. So it is our passion to provide the best quality care to improve our population health and improve patients’ quality of life and, in the meantime, maintain affordability for all.
Can you elaborate on the health equity concerns you highlighted related to heart failure?
In the beginning, when we studied heart failure treatment, really, health equity was not a primary focus. However, recent studies have revealed that we are seeing the different marginalized socioeconomic groups and the different racial groups have higher risk as well as lower clinical outcomes, even if they have similar access to care. So health equity is becoming more and more important to our health care leaders, as well as our entire industry as scientists focus. So, in Northern California, we have a diverse population, we have a very high percentage of African Americans, we have a very high percentage of Hispanic population, as well as Asian and Pacific Islanders. So, we really wanted to make sure that all of our patients across racial, across socioeconomic backgrounds, across payer mix, all receive the highest quality of care, within Sutter and without Sutter and within the entire region.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More
RFK Jr Claims HHS Has Not Fired Working Scientists, Canceled Lifesaving Research
May 15th 2025Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.
Read More